SCHEMBL807858

SCHEMBL807858

Cc1cc(-c2ccccc2)ccc1N

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 5/20 0.77
ALDH1A1 P00352 4/20 0.77
CYP3A4 P08684 4/20 0.77
TSHR P16473 2/20 0.77
HSD17B10 Q99714 3/20 0.52
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
KDM4E B2RXH2 2/20 0.52
MAPT P10636 2/20 0.52
HPGD P15428 2/20 0.52
ALOX12 P18054 2/20 0.52
USP2 O75604 1/20 0.52
LMNA P02545 1/20 0.52
HSP90AA1 P07900 1/20 0.52
GAA P10253 1/20 0.52
ALOX15 P16050 1/20 0.52
HTT P42858 1/20 0.52
IKBKB O14920 1/20 0.50
SMN1; SMN2 Q16637 3/20 0.49
HDAC3 O15379 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8954009 0.91 CYP3A4 (0.94) TDP1ALDH1A1CYP3A4TSHRHSD17B10
Orthotolidine SCHEMBL8061312 0.89 TDP1 (0.74) TDP1ALDH1A1CYP3A4TSHRHSD17B10
Orthotolidine SCHEMBL49414 0.88 CYP3A4 (1.00) TDP1ALDH1A1CYP3A4TSHRHSD17B10
Orthotolidine SCHEMBL29386552 0.88 CYP3A4 (1.00) TDP1ALDH1A1CYP3A4TSHRHSD17B10
Orthotolidine SCHEMBL29365329 0.88 CYP3A4 (1.00) TDP1ALDH1A1CYP3A4TSHRHSD17B10
Orthotolidine SCHEMBL11207210 0.87 TDP1 (0.71) TDP1ALDH1A1CYP3A4TSHRHSD17B10
Orthotolidine SCHEMBL7683641 0.86 CYP3A4 (0.77) TDP1ALDH1A1CYP3A4TSHRHSD17B10
Orthotolidine SCHEMBL11189493 0.85 CYP3A4 (0.94) TDP1ALDH1A1CYP3A4TSHRHSD17B10
Orthotolidine SCHEMBL2812115 0.85 CYP3A4 (0.94) TDP1ALDH1A1CYP3A4TSHRHSD17B10
Orthotolidine SCHEMBL20547383 0.85 CYP3A4 (0.94) TDP1ALDH1A1CYP3A4TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025100475-A1 COMPOSITION FOR IMAGE RECORDING AND METHOD FOR PRODUCING SAME キヤノン株式会社 2025-05-15 WO disclosed
CN-113620816-B Aromatic amine derivative organic electroluminescent material and device thereof 北京夏禾科技有限公司 2025-01-10 CN disclosed
WO-2024144176-A1 COMPOSITION FOR OPTOELECTRONIC DEVICE, ORGANIC OPTOELECTRONIC DEVICE, AND DISPLAY APPARATUS 삼성에스디아이 주식회사 2024-07-04 WO disclosed
CN-118250904-A Method for manufacturing circuit board 味之素株式会社 2024-06-25 CN disclosed
CN-111560171-B Resin composition 味之素株式会社 2024-06-18 CN disclosed
CN-118063932-A Resin composition 味之素株式会社 2024-05-24 CN disclosed
CN-111548625-B Resin composition 味之素株式会社 2024-04-05 CN disclosed
CN-111138856-B Resin composition 味之素株式会社 2024-01-23 CN disclosed
EP-4306612-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE Samsung Electronics Co., Ltd. (KR) 2024-01-17 EP disclosed
CN-117043991-A Polyimide compound, negative electrode material for lithium ion secondary battery using same, negative electrode for lithium ion secondary battery, and lithium ion secondary battery 胜高科技股份有限公司 2023-11-10 CN disclosed
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2010-04-08 US disclosed
EP-1914221-A1 PROCESS FOR PRODUCING BIARYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-04-23 EP disclosed
CN-1937994-A Keratin dyeing compounds, keratin dyeing compositions containing them and their use PROCTER & GAMBLE (US) 2007-03-28 CN disclosed
EP-1753428-A2 KINASE INHIBITORS AS THERAPEUTIC AGENTS Abbott Laboratories (US) 2007-02-21 EP disclosed
US-20060074102-A1 Kinase inhibitors as therapeutic agents ABBOTT LABORATORIES 2006-04-06 US disclosed
WO-2005110410-A2 KINASE INHIBITORS AS THERAPEUTIC AGENTS ABBOTT LABORATORIES (US) 2005-11-24 WO disclosed
US-6242115-B1 ELECTROLUMINESCENCE THE UNIVERSITY OF SOUTHERN CALIFORNIA 2001-06-05 US disclosed
WO-1999013691-A1 OLEDS CONTAINING THERMALLY STABLE ASYMMETRIC CHARGE CARRIER MATERIALS THE UNIVERSITY OF SOUTHERN CALIFORNIA (US) 1999-03-18 WO disclosed
US-4670566-A ANTIIFLAMMATORY AGENTS, ANTICOAGULANTS A. H. ROBINS COMPANY, INCORPORATED (US) 1987-06-02 US disclosed
US-4440785-A Methods of using 2-aminobiphenylacetic acids, esters, and metal salts thereof to treat inflammation A. H. ROBINS COMPANY, INC. (US) 1984-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074102-A1 Kinase inhibitors as therapeutic agents ABL1, MAP3K19, MAP3K20 TDP1 1395/4885ALDH1A1 2415/4885CYP3A4 2782/4885
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND NISCH, BLVRB, BBOX1 TDP1 4196/4885ALDH1A1 4339/4885CYP3A4 177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.